Jim Pang, M.D., PLLC in Cordova, TN offers Spravato treatment to alleviate your symptoms of depression and restore your quality of life. If you are struggling with treatment-resistant depression or major depressive disorder with suicidal thoughts or actions, call 901-752-4900 today to find out how Spravato can help you.
What is Spravato?
Spravato is a CIII nasal spray indicated for treatment-resistant depression in adults and major depressive disorder with suicidal thoughts or actions. Spravato is the S-enantiomer of racemic mixture, ketamine. Spravato is a non-selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, an inotropic glutamate receptor.
What should I expect while using Spravato?
Spravato is administered via single use nasal spray devices and is to be used in combination with oral anti-depressant therapy. Each single-use device delivers 28 mg of Spravato. The dosing schedule of Spravato is broken up into 2 phases: the induction phase (weeks 1-4), and the maintenance phase (weeks 4 to 8, then weeks 9-plus).
In the induction phase (weeks 1 to 4), on day 1, the initiation dose is 56 mg (2 devices). Subsequent doses in the induction phase may be 56 mg or 84 mg twice weekly based on efficacy and tolerability. In weeks 5 to 8 of the maintenance phase, either 56 mg or 84 mg may be administered once weekly. In the ninth week and thereafter, either 56 mg or 84 mg may be administered once weekly or once every 2 weeks. The frequency in weeks 9-plus is determined by the patient response and clinical judgment of the remission/response to treatment.
Spravato is to be administered under supervision of a healthcare provider. After Spravato is administered, the patient must be observed for a period of at least 2 hours at each treatment session due to sedative and dissociative adverse effects and the possibility of increased blood pressure.
Prior to each treatment of Spravato, a baseline blood pressure assessment is taken. After the administration of the medication, blood pressure must be re-evaluated after 40 minutes and when clinically indicated.
Patients will rest comfortably under the supervision of a member of our clinical team for approximately two hours. When you are released, you will need a friend or family member to drive you home. You may be tired for the rest of the day, but any fatigue will pass by the time you wake up the next morning.
Am I a good candidate for Spravato?
Spravato has shown great promise for adults with treatment resistant depression or major depressive disorder with suicidal thoughts or actions. As you know, depression is so much more than feeling sad-it’s a debilitating combination of symptoms that are different for each person. If conventional treatment options for depression have not relieved your symptoms Spravato may be a good option.